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Acute kidney injuryIn kidneys, each tubular epithelial cell contains a primary cilium that protrudes from the apical surface. Cil-
iary dysfunction was recently linked to acute kidney injury (AKI) following renal ischemia–reperfusion.
Whether ciliary regulation is a general pathogenic mechanism in AKI remains unclear. Moreover, the ciliary
change during AKI and its underlying mechanism are largely unknown. Here we examined the change of pri-
mary cilium and its role in tubular cell apoptosis and AKI induced by cisplatin, a chemotherapy agent with
notable nephrotoxicity. In cultured human proximal tubular HK-2 epithelial cells, cilia became shorter during
cisplatin treatment, followed by apoptosis. Knockdown of Kif3a or Polaris (cilia maintenance proteins) re-
duced cilia and increased apoptosis during cisplatin treatment. We further subcloned HK-2 cells and found
that the clones with shorter cilia were more sensitive to cisplatin-induced apoptosis. Mechanistically,
cilia-suppressed cells showed hyperphosphorylation or activation of ERK. Inhibition of ERK by U0126 pre-
served cilia during cisplatin treatment and protected against apoptosis in HK-2 cells. In C57BL/6 mice,
U0126 prevented the loss of cilia from proximal tubules during cisplatin treatment and protected against
AKI. U0126 up-regulated Polaris, but not Kif3a, in kidney tissues. It is suggested that ciliary regulation by
ERK plays a role in cisplatin-induced tubular apoptosis and AKI.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Cilia are tiny, membrane-enclosed organelles that protrude from the
apical side of the cell. Structurally, cilia contain nine sets of microtubule
doublets arranged in a circular patternwith (9 + 2) orwithout (9 + 0)
a central pair of microtubule singlets. In the human body including kid-
neys, most cells have a single, non-motile (9 + 0) cilium called primary
cilium. Ciliogenesis is a complex process involving microtubule poly-
merization and intraﬂagellar transport (IFT). IFT is a two-parallel pro-
cess of anterograde transport towards the ciliary tip of the axoneme by
the heterotrimeric kinesin-2 motor protein complex (Kif3a, Kif3b, Kap)
and retrograde transport facilitated by the motor protein dynein [1].
Dozens of factors have been reported to regulate the length of cilia [2].
The functions of primary cilia have been obscure for decades, however
recently cilia have been recognized to play pivotal roles in embryo de-
velopment, and cell and tissuehomeostasis. Primary ciliamay be the sig-
naling hub housing the receptors ofmultiple signalingmolecules such as
Wnt, Hedgehog, and Notch [2,3]. At the cellular level, primary cilia may, The Second Xiangya Hospital,
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l rights reserved.participate in the regulation of cell differentiation, proliferation, and ap-
optosis [4,5]. Notably, ciliary dysfunction contributes critically to the
pathogenesis of a large spectrum of human genetic diseases, named
ciliopathies [6]. In mice, deletion of KIF3a leads to stunted primary cilia
resulting in polycystic kidney disease (PKD) [7].
Interestingly, several recent studies have suggested a connection
between ciliary dysfunction and acute kidney injury (AKI). On one
hand, the loss of cilia seems to sensitize renal ischemia–reperfusion-
induced AKI and on the other, ischemic AKI can promote or accelerate
PKD in mice with ciliary defects [8–12]. Despite these notable obser-
vations, it is unclear whether ciliary regulation is involved speciﬁcally
in ischemia–reperfusion injury or in other types of AKI as well. More-
over, the ciliary change during AKI and its underlying mechanism are
largely unknown.
Cisplatin is a widely used chemotherapy drug for cancer treatment
[13]. However, the anti-cancer efﬁcacy of cisplatin is limited by its side
effects in normal tissues and organs, especially the kidneys [14–19].
Nephrotoxicity or AKI occurs in about one-third of patients undergoing
cisplatin treatment [15]. The pathogenesis of cisplatin AKI involves the
activation of multiple signaling pathways that cause tubular cell injury
and death, accompanied by inﬂammation and vascular damage in kid-
ney tissues [14–19]. Mitogen-activated protein kinases (MAPK), DNA
damage response, and oxidative stress are among the important signal-
ing pathways that contribute to kidney tubular injury during cisplatin
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pathways have been taken for renoprotection [14,15]. For example,
U0126, the MEK inhibitor that blocks ERK activation, has been reported
to attenuate cisplatin-induced kidney injury in mice and in cultured tu-
bular epithelial cells [10,20–23].
In the present study, we demonstrate that cilia are suppressed dur-
ing cisplatin treatment of HK-2 cells in vitro and mice in vivo. One of
the ciliary proteins that is reduced in expression is Polaris. The cells
with ciliary defects are sensitized to cisplatin-induced apoptosis.
U0126 can up-regulate Polaris and preserve cilia during cisplatin treat-
ment, accompanied by the prevention of tubular apoptosis and AKI. To-
gether, the results suggest a pathogenic role of ERK-mediated ciliary
dysfunction in AKI.
2. Materials and methods
2.1. Reagents and antibodies
Acetyl tubulin (#T7451) and β-actin (#A2228) antibodies were pur-
chased from Sigma (St. Louis, MO). Kif3a (#611508) and Polaris
(#13967-1-AP) antibodies were acquired from BD Transduction Labora-
tory (Franklin Lakes, NJ) and Proteintech Group (Chicago, IL). Antibodies
to MAPK (P-ERK at Thr202/Tyr204, #9101) and p53 (P-p53 at Ser15,
#9284; p53, #9282) pathways were obtained from Cell Signaling Tech-
nologies (Cambridge, MA). Carbobenzoxy-Asp-Glu-Val-Asp-7-amino-
4-triﬂuoromethyl coumarin (DEVD-AFC) and 7-amino-4-triﬂuoromethyl
coumarin (AFC)were bought fromEnzymeSystemsProducts (Livermore,
CA). Cyclophilin B (CypB) antibody (#ab16045) was purchased from
Abcam (Cambridge, MA). Secondary antibodies for Western blot were
from Jackson ImmunoResearch (West Grove, PA) and for immunoﬂuo-
rescence staining from Chemicon (Temecula, CA) respectively. For apo-
ptosis assay by ﬂow cytometry, a kit (#556420) containing annexin
V-FITC and propidium iodide (PI) was obtained from BD Pharmingen
(San Jose, CA). Other reagents were from Sigma unless speciﬁcally
indicated.
2.2. Cisplatin-induced AKI in mice
Eight-week old C57BL/6 male mice, purchased from the Jackson
Laboratories, were housed for one week before experiments in the
animal facility of the Charlie Norwood VA Medical Center at Augusta.
These mice had free access to water and regular chow. Animal exper-
iments were conducted according to the guidelines approved by the
Institutional Animal Care and Use Committee of the Charlie Norwood
VA Medical Center and Medical College of Georgia. Three groups of
mice (4 mice/group) were set up for experiments: Group I was
injected with saline as control; Group II was injected with 30 mg/kg
cisplatin intraperitoneally; Group III was injected with 10 mg/kg
U0126 via tail vein and one hour later was injected with 30 mg/kg
cisplatin intraperitoneally. Mice were sacriﬁced at 72 h after cisplatin
administration to collect blood for measurement of the blood urea ni-
trogen (BUN) and serum creatinine (SCr) respectively using a com-
mercial kit (Stanbio Laboratories, Boerne, TX) and the picric acid
method established in this lab [24]. Kidneys were also harvested for
histological analysis and immunoblotting [25].
2.3. Subcloning of HK-2 cells
HK-2 cells from theATCC (CRL-2190)were cultured in theDMEM/F12
media and passaged at a dilution concentration of 500 cells in 1 ml. After
5 weeks of growth, a total of 40 single colonies were picked up and am-
pliﬁed. After 3-day post conﬂuence, cellswere stainedwith anti-acetyl tu-
bulin antibody. Cilia frequency (cells with cilia/total cells) was calculated
and compared among all the clones. Four clones of cells (C4, 28, 32, 39)
demonstrated >75% cilia frequency while in ﬁve clones (C3, 8, 10, 13,14) cilia frequency was b25%. Cilia frequency ranged from 25% to 75%
in the rest of the clones.
2.4. Establishment of Kif3a and Polaris knockdown cells
The HK-2 C4 clone with good cilia was used for establishment of
Kif3a and Polaris knockdown cells. Brieﬂy, four Kif3a shRNA constructs
and ﬁve Polaris shRNA constructs were individually mixed well with
theMISSION Lentiviral PackagingMix (SHP001, Sigma), and transfected
into HEK293FT cells by Lipofectamine 2000 (Invitrogen, Grand Island,
NY). Culture media were replaced with fresh media 24 h after transfec-
tion, and collected at 36 h. 100 μl of culturemedia containing virion par-
ticles were added to HK-2 cells for selection by puromycin (1 μg/ml).
Meanwhile, cells transduced with the MISSION Non-Target shRNA Con-
trol Transduction Particles (SHC002V, Sigma) were used as the control.
Knockdown clones were conﬁrmed by immunoblotting with respective
antibodies.
2.5. Immunostaining and quantiﬁcation of the cilia length and frequency
in kidney tissues and cultured cells
Tissue processing: After 24 h of ﬁxation in 4% paraformaldehyde,
mouse kidneys were transferred to 70% ethanol, processed with
Shandon Citadel 100 (Thermal Fisher Scientiﬁc, Waltham, MA) over-
night, and then embedded in parafﬁn. Kidneys were sectioned at 7 μm
(Leica RM2025, Germany) and dried overnight before deparafﬁnization
and rehydration through graded concentrations of ethanol. Antigen re-
trieval was done by putting slides in the boiling retrieval buffer (10 mM
sodium citrate pH 6.0, 0.05% tween-20). Cell ﬁxation: Cells were ﬁxed in
4% paraformaldehyde/2% sucrose solution and permeabilized with 0.1%
Triton X-100. Immunostaining was described in detail previously [26].
Brieﬂy, cells and tissue sections were blocked by bovine serum albumin
(BSA) for 1 h. After incubationwith primary antibodies for 1 h, cells and
tissue sections were washed with phosphate buffered saline (PBS), and
then incubated with secondary antibodies for another hour. Slides
were mounted by the Prolong Gold antifade reagent with DAPI
(4′-6-diamidino-2-phenylindole) (P36931, Sigma). Alternatively,
nuclei were stained with Hoechst 33342 (H-1399, Invitrogen). All
the procedures were performed at room temperature. For the
image analysis, Zeiss Axio ﬂuorescence and confocal microscopes
(Carl Zeiss Inc., Thornwood, NJ) were used. The confocal microscope
was equipped with the LSM Image analysis system and used for the
measurement of the cilia length and quantiﬁcation of cilia frequency.
2.6. Protein extraction from tissue and cell samples and immunoblotting
Proteins from kidney tissues and cells were extracted with the SDS
lysis buffer as previously shown [25]. Frozen kidney tissues were ho-
mogenized in SDS buffer on ice. Similar to protein extraction from
cells, samples were centrifuged at 15,000 rpm for 10 min. Supernatants
were used for protein analysis. Protein sampleswere electrophoresed in
a 10% Bis-Tris gel and transferred to the PVDF nylon membranes
(Bio-Rad, Hercules, CA). After blocking with 5% non-fat dry milk (Lab
Scientiﬁc, Livingston, NJ) in PBS for 1 h, the ﬁlter was incubated with
the primary antibody and washed with PBS/0.1% Tween 20 (MP
Biomedicals, Santa Ana, CA). The ﬁlter was ﬁnally incubated with the
secondary immunoglobulins conjugated with the horseradish peroxi-
dase. The bound antibodies were detected with the Detection Reagent
(Pierce, Rockford, IL). Quantiﬁcation of the band intensity was accom-
plished with the NIH Image J software.
2.7. Cisplatin treatment, morphologic analysis, and caspase activity assay
in HK-2 cells
Morphologic analysis of apoptotic cells and caspase activity assay
were done as described previously [27]. For morphologic analysis of
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Hoechst 33342 for 5 min before microscope examination. Cellular
and nuclear morphology was evaluated with phase-contrast and
ﬂuorescence microscopy. The observable features of apoptotic cells
included the cellular shrinkage, nuclear condensation and fragmenta-
tion, as well as the formation of apoptotic bodies. Five ﬁelds with ap-
proximately 200–300 cells per ﬁeld were examined to estimate the
percentage of apoptotic cells. For the caspase activity assay, 50 to
100 μg of cell lysates was added to an enzymatic reaction containing a
ﬂuorogenic substrate for caspases. Emitted ﬂuorescence during reaction
was quantiﬁed at excitation 360 nm/emission 530 nm. Caspase activity
was calculated based upon a standard curve and expressed as the
nanomolar amount of the liberated AFC by 1 mg protein of cell lysates.2.8. Apoptosis analysis with annexin-V-FITC and propidium iodide
Apoptosis was further quantiﬁed by ﬂuorescence-activated cell
sorting (FACS) after annexin V-FITC and propidium iodide (PI) staining
as described before [27]. Cisplatin-treated cells were trypsinized and
centrifuged together with supernatants harvested. Pelleted cells were
washed with cold PBS, resuspended in 100 μl Binding Buffer at a con-
centration of 1 × 106/ml, and transferred into a 1.5 ml Eppendorf
tube. Annexin V-FITC and PI were added for 15-minute incubation in
the dark at room temperature. Finally, 400 μl Binding Buffer was
added to each tube for analysis by a BD FACSCalibur ﬂow cytometer
(BD Biosciences, San Jose, CA).2.9. Statistics
Valueswere expressed asmean ± standard deviation (SD). Student's
T-Test and chi-square test were used for comparison. Spearman correla-
tion was used to calculate the correlation coefﬁcient of two factors.
p b 0.05 was considered statistically signiﬁcant.3. Results
3.1. Suppression of cilia during cisplatin treatment of HK-2 cells
To study the effect of cisplatin on cilia length and frequency, we
applied cisplatin into HK-2 cells in a time course manner. After 2-
and 4 h of cisplatin treatment, cilia length and frequency remained
unchanged. However, cisplatin treatment for 8–16 h led to signiﬁcant
decreases in cilia length and frequency as compared with the control
group (Fig. 1A). Cilia length was shortened to about half of control at
8-hour treatment and was close to zero at 16-h of treatment. Like-
wise, cilia frequency was reduced from ~70% in control to ~5% after
16-hour treatment. Consequently, cilia were barely detected.3.2. Establishment of cilia-suppressed cell clones
To study the relationship between cilia and apoptosis, we ﬁrst
sub-cloned HK-2 cells and examined cilia by immunostaining to di-
vide the cell clones into three groups, i.e., the cilium-long (Cilium-L),
cilium-short (Cilium-S), and cilium-middle. A big difference in cilia
length and frequency was observed between the Cilium-L (C4, C28)
and Cilium-S (C13, C14) cells (Fig. 2A). Additionally, we knocked
down Kif3a and Polaris with shRNAs (Fig. 2B). By immunoblotting,
it was shown that high efﬁciency of knockdown was achieved in
Kif3a-2 and Polaris-2 and -3 clones. Compared with the non-target
shRNA transfected control, the knockdown cells exhibited signiﬁcant-
ly shorter cilia, although their cilia frequency was only marginally re-
duced as revealed by immunostaining (Fig. 2B).3.3. Cilia-suppressed cells are more sensitive to cisplatin treatment
We tested the sensitivity difference of Cilium-S and Cilium-L cells
to cisplatin treatment. Compared with Cilium-L cells, more Cilia-S
cells underwent apoptosis after 16 h of cisplatin treatment at a con-
centration of 100 μM (Fig. 3A). In order to conﬁrm this observation,
we used three doses of cisplatin (50, 100, 200 μM) to treat Kif3a
and Polaris knockdown cells. As shown in Fig. 3B, in each of the cis-
platin concentrations a higher percentage of apoptotic cells were ob-
served in Kif3a or Polaris knockdown cells than the non-target shRNA
transfected cells. By FACS analysis of annexin V-FITC/PI staining, we
further conﬁrmed that more apoptosis was induced by cisplatin in Po-
laris knockdown cells than the non-target shRNA transfected cells
(not shown). Together, the results indicate that ciliary suppression
sensitizes HK-cells to cisplatin-induced apoptosis.
3.4. Heightened ERK1/2 activation in cilia-suppressed cells during
cisplatin treatment
MAPKs, especially ERK1/2, play important roles in tubular cell
apoptosis and kidney injury during cisplatin treatment [23,28].
Thus, to understand the mechanism of cisplatin sensitivity of
cilia-suppressed HK2 cells, we analyzed ERK1/2 phosphorylation
in Cilium-L and -S cells. As shown in Fig. 4A, cisplatin-induced
ERK1/2 phosphorylation or activation in Cilia-S cells was markedly
higher than that in Cilia-L clones. In line with this observation, Kif3a
and Polaris knockdown cells showed signiﬁcantly higher ERK1/2
phosphorylation than control shRNA-transfected cells following
cisplatin treatment (Fig. 4B).
3.5. Inhibitory effect of U0126 on cisplatin-induced caspase activation in
cilia-suppressed cells
Based on the above results, we hypothesized that the heightened
ERK activation in cilia-suppressed cells may underlie their sensitivity
to cisplatin-induced apoptosis. To pursue this possibility, we exam-
ined the effect of U0126, a speciﬁc pharmacological inhibitor of
MEK that blocks ERK1/2 phosphorylation and activation. We initially
tested ﬁve different doses of U0126 in HK-2 cells and found that 5 μM
was able to block ERK phosphorylation during cisplatin treatment
(Fig. 5A). To quantify apoptosis, we measured caspase activity. As
shown in Fig. 5B, the cells with short cilia (Cilia-S) were more sensi-
tive to cisplatin-induced caspase activation or apoptosis and impor-
tantly, U0126 largely abrogated the injury sensitivity of Cilium-S
cells. Similarly, U0126 blocked cisplatin-induced caspase activation
in Kif3a and Polaris knockdown cells, while only marginal effects
were shown in non-target shRNA transfected cells (Fig. 5C). These ob-
servations support a role of heightened ERK activation in the sensitiv-
ity of ciliary defective cells.
3.6. U0126 increases cilia length and frequency in HK-2 cells
To study whether U0126 protects HK-2 cells by promoting
ciliogenesis, we quantiﬁed the length and frequency of cilia. In
untreated HK-2 cells, U0126 signiﬁcantly increased the cilia length
and frequency (Fig. 6A). In Cilia-L (C28) and Cilia-S (C13) cells
treated with cisplatin, U0126 increased cilia length from almost
none to 0.5–1.5 μm, and frequency to 10–20% (Fig. 6B). Likewise,
cilia length and frequency was increased by U0126 to some extent
in Polaris knockdown cells (Fig. 6C).
3.7. Inverse correlation between cilia length and caspase activity
To study the correlation of the cilia length and caspase activity, we
measured the changes of cilia length and caspase activity during cisplat-
in treatment and calculated the correlation coefﬁcient. As shown in
Fig. 1. Decreases of cilia length and frequency during cisplatin treatment. HK-2 cells were cultured with or without 100 μM cisplatin for 2, 4, 8, and 16 h for immunostaining with
anti-acetyl tubulin antibody. Nuclei were stained with DAPI. (A) Representative images. Scale bar, 10 μm. (B) Cilia length. Cilia length was measured in n > 30 cells/group to cal-
culate the average values. After measurement, cilia were divided into different length ranges to calculate their length distribution (n > 30 cells/group). (C) Cilia frequency. Cilia
frequency was indicated by the percentage of cells with detectable cilia. For each group, the cells in 5 different view ﬁelds of microscope were evaluated. Open bar,
DMSO-treated control; ﬁlled bar, cisplatin-treated group. *p b 0.001 vs. DMSO-treated control.
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activity. Upon U0126 treatment, Cilia length inversely correlated with
caspase activity (correlation coefﬁcient r = −0.6) (Fig. 7B). The most
effective dose of U0126 in lengthening cilia was achieved at 1 μM
(Fig. 7C).Fig. 2. Establishment of cilia-suppressed cell clones. (A) Subcloning of cells with long and sh
and short cilia (e.g. C13 and C14) revealed by immunoﬂuorescence of acetyl tubulin. Cilia
mined from >4 different view-ﬁelds of microscopy. (B) Establishment of stable Kif3a or P
one non-target shRNA sequence were separately transduced into HK-2 cells using a retrov
in knockdown cells were reduced as compared with the non-target sequence transfected c
antibodies. *p b 0.001 Cilia-S (C13, C14) vs. Cilia-L (C4, C28), and knockdown (Kif3a-2, Pol3.8. U0126 inhibits ERK activation, preserves cilia, and protects against
cisplatin-induced kidney injury in mice
As reported previously [20], cisplatin induced ERK phosphoryla-
tion or activation in kidney tissues in mice, which was suppressedort cilia. HK-2 cells were subcloned to select cell clones with long cilia (e.g. C4 and C28)
were measured in different cell clones (n > 20 cells/group) and cilia frequency deter-
olaris knockdown clones. Constructs of four Kif3a and ﬁve Polaris shRNAs as well as
iral system. Cilia length (n > 20 cells/group) and frequency (5 different view-ﬁelds)
ontrol cells. Knockdown efﬁciency was conﬁrmed by immunoblotting with respective
aris-2, Polaris-3) vs control. Nuclei were stained with DAPI. Scale bar, 10 μm.
Fig. 3. Cilia-suppressed cells are more sensitive to cisplatin treatment. (A) Cisplatin-induced apoptosis in long cilia C4 and short cilia C13 cells. The cells were treated with cisplatin
at 100 μM for 16 h and then stained by Hoechst 33342. (B) Cisplatin-induced apoptosis in Kif3a and Polaris knockdown cells and control shRNA transfected cells. The cells were
treated with 50, 100 or 200 μM cisplatin for 16 h and then stained by Hoechst 33342. Cisplatin-representative cell and nuclear images were collected by phase (×20) and ﬂuores-
cence microscopy (top × 20; bottom × 40). For quantiﬁcation, apoptotic cells were counted from >4 different view ﬁelds of microscopy. *p b 0.05, **p b 0.01, Cilia-S vs Cilia-L, or
knockdown vs control.
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indicated by increases in BUN and serum creatinine, which were
also partially suppressed by U0126 (Fig. 8B). We further analyzed
the changes in cilia in proximal tubules. As shown in Fig. 9A, primary
cilia were rarely observed in the injured dilated proximal tubules
after cisplatin treatment, although the cilia in normal-looking proxi-
mal tubules did not show signiﬁcant changes (Fig. 9B). Interestingly,Fig. 4. Heightened ERK activation by cisplatin in cilia-suppressed cells. Cells were treat-
ed with cisplatin (100 μM) for 16 h to collect whole cell lysate for immunoblotting of
P-ERK and cyclophilin B (CypB: loading control). Densitometry was conducted for
semi-quantiﬁcation. (A) P-ERK in long cilia (C4, 28) cells and short cilia (C13, 14)
clones. The experiments were repeated twice. For densitometry, C4 and C28 values
were combined as Cilia-L, while C13 and C14 as Cilia-S. (B) P-ERK in Kif3a and Polaris
knockdown clones (n = 3/each clone). #p b 0.01 Cilia-S vs Cilia-L; *p b 0.05 Kif3a or
Polaris knockdown vs control.in mice pre-treated with U0126, a signiﬁcantly higher frequency of
cilia was detected in injured tubules of kidneys than those in the
only cisplatin-treated mice (Fig. 9C). These results suggest that by
inhibiting ERK, U0126 may preserve cilia and protect kidney tubules
and tissues during cisplatin treatment.
3.9. Cisplatin suppresses the expression of Polaris in mouse kidneys and
HK-2 cells: effect of U0126
To explore the mechanisms of ciliary suppression upon cisplatin
treatment, we examined the expression of Polaris and Kif3a, key pro-
teins in the maintenance of ciliary homeostasis. Following cisplatin
treatment, Kif3a was up-regulated in kidney tissues, whereas Polaris
was mildly suppressed (Fig. 10A). Consistently, in HK-2 cells cisplatin
signiﬁcantly reduced Polaris expression after 8 to 16 h of treatment
(Fig. 10B). Notably, U0126 increased the expression of Polaris in kidney
tissues during cisplatin-treatment inmice (Fig. 10A), whichwas accom-
panied by the preservation of cilia and renoprotection (Figs. 8, 9).
4. Discussion
Ciliary dysfunction has been linked to AKI following renal ischemia–
reperfusion [8–12]. However, it is unclear whether this is speciﬁc for is-
chemic AKI or a general pathogenic process in kidney injury. Moreover,
the ciliary change during AKI and its underlying mechanism are largely
unknown. In this study, we demonstrated ciliary disruption using
cisplatin treatment of HK-2 cells in vitro and mice in vivo. Using
subcloned as well as Kif3a and Polaris knockdown HK-2 cells,
we further showed that ciliary defective cells are sensitized to
cisplatin-induced apoptosis. Mechanistically, our results indicate
that ERK1/2 may be responsible for ciliary disruption during cis-
platin treatment by suppressing speciﬁc ciliary maintenance pro-
teins such as Polaris.
Ciliogenesis mainly depends on microtubule polymerization, which
is orchestrated by cargo transport facilitated by kinesin-2 complex to-
wards the tip and cytoplasmic dynein towards the base of cilia. In this
Fig. 5. Inhibitory effect of U0126 on cisplatin-induced caspase activation in cilia-suppressed cells. (A) Effects of various doses of U0126 on ERK phosphorylation during cisplatin
treatment of HK-2 cells. U0126 of 0.1–10 μM were added during 100 μM cisplatin treatment to collect lysate at 16 h to analyze P-ERK and cyclophilin B. (B) (C) HK-2 cell clones
were treated with 100 μM cisplatin treatment for16 h in the absence or presence of 5 μM U0126. Cell lysate was collected to measure caspase activity. Caspase activity was mark-
edly reduced by U0126, especially in cilia-suppressed cells including both Cilia-S and Kif3a/Polaris knockdown cells. *p b 0.05, **p b 0.01 cilia-S vs cilia-L, or knockdown (Kif3a or
Polaris) vs control; #p b 0.05, ##p b 0.01 U0126 vs non-U0126.
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proteins lead to shortened cilia inmice [2,7,29]. Our study demonstrates
for the ﬁrst time that cisplatin reduces the cilia length and frequency
not only in cultured human HK-2 cells but also in proximal tubular
cells in mouse kidneys. Interestingly, while Kif3a was shown to be
markedly up-regulated during cisplatin treatment, Polaris was de-
creased. Although these results do not exclude a regulation of other
IFT or ciliary proteins, it is suggested that ciliary disruption during
cisplatin treatment may result from the imbalance between these
proteins. We propose that upon cell stress or injury, key ciliary proteins
are destabilized or become non-functional, resulting in the resorption
or disassembly of cilia. In support of this possibility, U0126 increased
Polaris and preserved cilia in kidney tissues during cisplatin treatment
in the present study.Fig. 6. Inhibition of ERK by U0126 increases cilia length and frequency in HK-2 cells. (A) Sh
noﬂuorescence of acetyl tubulin was analyzed to reveal cilia. Cilia were measured to deter
cilia. (B) Short cilia C28 and long cilia C13 cells were treated with 100 μM cisplatin for 16
cence of acetyl tubulin. After cisplatin treatment, the cells had no or very short cilia. U0126
ment. (C) Polaris knockdown and non-target shRNA transfected control cells were treated
by immunoﬂuorescence of acetyl tubulin. U0126 preserved cilia during cisplatin treatme
cells were counted. Cells from >4 different view ﬁelds of microscopy were calculated to
Scale bar, 10 μm.At the cellular level, cilia are known to play important roles in the reg-
ulation of cell cycle and cell proliferation [4,5]. However, relatively less is
known about the involvement of cilia in the regulation of cell death or
survival. Our data indicate that the decrease of cilia length and frequency
preceded caspase activation during cisplatin treatment of HK-2 cells,
suggesting that ciliary reabsorption may be an early event in apoptosis.
Notably, the cells with ciliary suppression were shown to be more sensi-
tive to cisplatin-induced apoptosis, supporting a role of cilia and related
signaling in cell survival. Consistently, in vivo in mouse kidneys cilia be-
came shortened following cisplatin treatment and U0126 preserved
cilia, which was accompanied by the protection of kidney tissues and
renal function. It remains unclear how cilia promote cell survival and
maintain tissue integrity. Nevertheless, compared to the cells with nor-
mal or long cilia, during cisplatin treatment cilia-suppressed cells showedort cilia HK-2 C28 cells were incubated with or without 5 μM U0126 for 16 h. Immu-
mine their length and the % cells with cilia was calculated to indicate the frequency of
h in the absence or presence of 5 μM U0126. Cilia were revealed by immunoﬂuores-
increased cilia length and frequency in both C28 and C13 cells during cisplatin treat-
with 100 μM cisplatin in the absence or presence of 5 μMU0126. Cilia were revealed
nt as indicated by cilia length and frequency. For cilia length measurement, 20 to 60
determine the cilia frequency.*pb0.01, **p = 0.001 cisplatin + U0126 vs cisplatin.
Fig. 7. Inverse correlation of cilia length and caspase activation during cisplatin treatment of HK-2 cells. (A) Time-dependent reduction of cilia length and caspase activation during
cisplatin treatment. Dashed line—increase in caspase activity; solid line—decrease in cilia length. (B) Inverse correlation of cilia length and caspase activity changes upon U0126
treatment. Empty triangle, Cilia-L; ﬁlled triangle, Cilia-S; empty square, non-target control; ﬁlled square, knockdown clones. Each point represented the average of respective
values. (C) Increase of cilia length after 0.1–10 μM U0126 treatment in HK-2 cells (>25 cells/group). *p b 0.05 U0126 vs control.
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protein kinase in cisplatin nephrotoxicity [23,28]. It is proposed that by
suppressing injury signaling and enhancing survival pathways, cilia
may help cells cope with stress and pathological conditions. As tiny or-
ganelles protruding from cell surface, cilia have been proposed to be the
sensors to physical, chemical, and biological signals. It is therefore not
far-fetched to speculate that in response to cell stress, cilia may function
to sense the signals from the environment, including those of growth fac-
tors, for cell survival. As a result, the loss or dysfunction of cilia may sen-
sitize cells to apoptosis.
Our study reveals an interesting relationship between ERK and
cilia. On one hand, suppression of cilia resulted in hyper-activation
of ERK in HK-2 cells, suggesting that cilia play a role in quenching
ERK. On the other hand, inhibition of ERK by U0126 resulted in the
preservation of cilia during cisplatin treatment, suggesting that ERK
contributes to ciliary disruption in this pathological condition. It is
unclear how cilia modulate ERK, but as suggested above, one possibil-
ity is that cilia may sequester ERK and/or key proteins responsible for
ERK activation. For the role of ERK in ciliary disruption, we speculate
that ERK may destabilize some of the key IFT proteins to disrupt cili-
ary homeostasis. In support of this, cisplatin induced ERK activation
and concomitant decreases in Polaris in kidney tissues and HK-2Fig. 8. Inhibition of ERK activation by U0126 protects against cisplatin-induced kidney injur
fect of U0126. Total 11 C57/Bl6 mice (male, 8 weeks) were divided into 3 groups: Group I h
cisplatin; and Group III had 4 mice injected with 30 mg/kg cisplatin and 10 mg/kg U01
phospho-ERK and cyclophilin B (CypB). The blots were also subjected to densitometry to
#p b 0.01 cisplatin + U0126 vs cisplatin. (B) Effect of U0126 on cisplatin-induced decreas
measure BUN and serum creatinine (SCr). *p b 0.01, **p b 0.001 cisplatin vs control; #p b 0cells. Moreover, inhibition of ERK by U0126 enhanced the expression
of Polaris and preserved cilia (Figs. 8–10). Obviously, further investi-
gations are needed to analyze other ciliary or IFT proteins that may be
subjected to ERK regulation. In addition, it is important to delineate
the molecular mechanism whereby ERK regulates these proteins. In-
deed, similar role of ERK in regulation of cilia length has been
shown in endothelial cells [30,31].
The protective effect of U0126 in cisplatin-induced tubular cell apo-
ptosis and AKI in animals has been demonstrated by several previous
studies. Mechanistically, U0126 may modulate mitochondrial function,
sodium transport as well as decreasing inﬂammation and apoptosis
[15,20,21]. Although detailed analysis of apoptosis in vivo by methods
such as measuring caspase activity was not conducted in the current
study, the pathogenic role of apoptosis in cisplatin-induced AKI and
the effect of U0126 on caspase activation in HK2 cells (Fig. 5) suggest
that a major effect of U0126 on cisplatin-induced AKI is through sup-
pressing apoptosis. The results suggest a new cellular mechanism of
the cytoprotective effects: by attenuating ERK, U0126 may protect
cells and tissues against injury and cell death bymaintaining the prima-
ry cilia in proximal tubular cells. Certainly, these mechanisms are not
mutually exclusive, suggesting the ERK may target multiple pathways
or cellular processes to induce cell death and tissue damage duringy. (A) ERK activation in kidney tissues during cisplatin treatment and the inhibitory ef-
ad 4 mice injected with saline as control; Group II had 3 mice injected with 30 mg/kg
26. After 3 days of treatment, kidney tissues were collected for immunoblotting of
semiquantify P-ERK/CypB to indicate ERK activation. *p b 0.001 cisplatin vs control;
e of renal function. Blood samples were collected at the end of 3 days of treatment to
.05, ##p b 0.01 cisplatin + U0126 vs cisplatin.
Fig. 9. Preservation of cilia by U0126 in dilated kidney tubules during cisplatin treatment of mice. Experimental conditions were as described in Fig. 8. Kidney tissues were co-stained for
cilia (acetyl tubulin immunoﬂuorescenc—red), proximal tubules (LTA—green), and cell nuclei (DAPI—blue). (A) Representative image of kidney tissues. In normalmice (control), the ﬁne
structure of primary cilia in proximal tubuleswas observed (white arrow). However, cilia were rarely found in the injured/dilated tubules of cisplatin-treatedmice (n > 20) (A—right side
images), whereas primary cilia appeared normal in non-dilated proximal tubules (A—left side images). With U0126 treatment, an appreciable proportion of primary cilia survived the
cisplatin treatment in the dilated tubules (white arrow). Please note, LTA failed to label the dilated proximal tubules due to the loss of brush borders. One representative kidney section
from each group was presented. G, glomerulus. Scale bar, 30 μm. (B) Cilia length. (C) Cilia frequency in dilated tubules. *p b 0.01 cisplatin + U0126 vs cisplatin.
1589S. Wang et al. / Biochimica et Biophysica Acta 1832 (2013) 1582–1590AKI. Nonetheless, a protective role of ERK has also been demonstrated
in renal systems under certain circumstances, such as ischemic
preconditioning and adenosine –mediated protection [28,32,33].
Although the exact underlying mechanism remains unclear, theFig. 10. Cisplatin suppresses the expression of Polaris in mouse kidneys and HK-2 cells: effe
kidneys. Kidney tissues were collected after 3 days of saline control, cisplatin, or cisplatin +
cisplatin treatment, Kif3a was markedly induced, while Polaris expression was marginally
vs control; #p b 0.05 cisplatin + U0126 vs cisplatin. (B) Time-dependent decreases in Polar
the expression of Polaris was reduced signiﬁcantly. *p b 0.05 cisplatin vs control.dichotomous role of ERK may be related to the differences of the inju-
ry/stress and the cell/tissue types examined.
In conclusion, our results indicate that ciliary disruption may be a
general pathogenic process in AKI. During cisplatin treatment, ciliaryct of U0126. (A) Effect of cisplatin and U0126 on Kif3a and Polaris expression in mouse
U0126 treatment for immunoblot analysis and subsequent densitometry. Following
suppressed. U0126 reversed the suppression of cisplatin on Polaris. *p b 0.01 cisplatin
is during cisplatin treatment of HK-2 cells. Upon 8- and 16-hour treatment of cisplatin,
1590 S. Wang et al. / Biochimica et Biophysica Acta 1832 (2013) 1582–1590disruptionmay result from ERK-mediated suppression of ciliary proteins
such as Polaris. Ciliary disruption sensitizes cells to injurious signaling
and apoptosis in renal tubular cells, contributing to kidney tissue dam-
age. Preserving cilia may offer a new therapeutic strategy for AKI.
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